每经AI快讯,4月10日,荣昌生物(688331.SH)公告称,公司近日收到国家药监局核准签发的《药品注册证书》,维迪西妥单抗联合特瑞普利单抗用于治疗HER2表达的局部晚期或转移性尿路上皮癌的新适应症上市申请获得批准。这是维迪西妥单抗在国内获批的第五项适应症。该适应症获批基于一项Ⅲ期临床试验结果,研究显示相比传统含铂化疗,该联合方案在无进展生存期和总生存期上均具有显著改善,且安全性更优。此次获批将...
Source Link每经AI快讯,4月10日,荣昌生物(688331.SH)公告称,公司近日收到国家药监局核准签发的《药品注册证书》,维迪西妥单抗联合特瑞普利单抗用于治疗HER2表达的局部晚期或转移性尿路上皮癌的新适应症上市申请获得批准。这是维迪西妥单抗在国内获批的第五项适应症。该适应症获批基于一项Ⅲ期临床试验结果,研究显示相比传统含铂化疗,该联合方案在无进展生存期和总生存期上均具有显著改善,且安全性更优。此次获批将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.